Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies
- 7 May 2007
- journal article
- review article
- Published by Elsevier
- Vol. 10 (3) , 81-100
- https://doi.org/10.1016/j.drup.2007.03.003
Abstract
No abstract availableKeywords
This publication has 199 references indexed in Scilit:
- MAP kinase pathways: The first twenty yearsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- A common signaling cascade may underlie “addiction” to the Src, BCR-ABL, and EGF receptor oncogenesCancer Cell, 2006
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006
- Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesisNature Reviews Cancer, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol‐3 kinase pathways in non‐small cell lung cancer cellsInternational Journal of Cancer, 2005
- Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibitionNature Structural & Molecular Biology, 2004
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Specificity and mechanism of action of some commonly used protein kinase inhibitorsBiochemical Journal, 2000